Aligos Therapeutics (ALGS) Retained Earnings (2019 - 2026)

Aligos Therapeutics has reported Retained Earnings for 8 years, with the latest figure at -$665.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 15.71% year-over-year to -$665.2 million; the trailing twelve-month figure through Mar 2026 stood at -$665.2 million (down 15.71% YoY), and the FY2025 full-year result was -$642.2 million, down 3.92% from the prior year.
• Retained Earnings for Q1 2026 stood at -$665.2 million, down from -$642.2 million in the prior quarter.
• The five-year high for Retained Earnings was $499000.0 in Q1 2023, with the low at -$665.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$428.9 million across 5 years, with a median of -$486.8 million in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 142768.53% — and 2023, when it soared 144.61%.
• Aligos Therapeutics' Retained Earnings stood at -$399.1 million in 2022, then slipped by 21.97% to -$486.8 million in 2023, then fell by 26.95% to -$618.0 million in 2024, then retreated by 3.92% to -$642.2 million in 2025, then slipped by 3.58% to -$665.2 million in 2026.
• The last three Retained Earnings figures came in at -$665.2 million (Q1 2026), -$642.2 million (Q4 2025), and -$622.3 million (Q3 2025), per Business Quant data.